Efficacy and Toxicity of Cisplatin and Capecitabine Combination in the First-Line Treatment of Patients with Advanced Gastric Cancer: A Multicenter Study by the Anatolian Society of Medical Oncology

Basit Öğe Kaydı
dc.contributor.authorCiltas, Aydin
dc.contributor.authorBuyukberber, Suleyman
dc.contributor.authorTopcu, Turkan O.
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorUyeturk, Ummugul
dc.contributor.authorCihan, Sener
dc.contributor.authorSendur, Mehmet A.
dc.date.accessioned2024-04-24T17:24:48Z
dc.date.available2024-04-24T17:24:48Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractGastric cancer is an important public health problem which comprises 10% of all cancers and 12% of all cancer related deaths all over the world. Because of the differences in patient populations and treatment schemes in various studies, standard practice for advanced stage gastric cancer has not been fully established. The aim of this study was to assess the use of cisplatin and capecitabine combination regimen in real-world clinical practice. Medical records of 76 male and 37 female metastatic gastric cancer patients treated with first-line cisplatin and capecitabine combination between February 2006 and December 2009 were retrospectively analyzed in 11 centers of the Anatolian Society of Medical Oncology. Patients previously treated with chemotherapy were excluded from the analysis. The median age of the patients was 64 years (range, 28-83). Seventy-six (67.2%) patients were males and 37 (32.7%) females. Most of the patients were metastatic (n= 85, 75.2%) at the time of initial diagnosis. The most common sites for metastasis were liver (65.9%), lung (11.3%), peritoneum (23.8%) and local recurrence (15.9%) with multiple metastases in 9.7% of the patients. The mean follow-up period of all patients was 41 months (range 12-61). Overall response rates was 33.6%, while disease control rate (DCR) was 72.6 %. Median Progression-free survival was 4.7 months (95% CI 3.75-6.49) and median overall survival was 11.1 months (95% CI 5.58-10.98). The most common grade 3-4 adverse events were anemia (8.3%), nausea-vomiting (3.8%) and diarrhea (1.8%). In terms of efficacy, toxicity and convenience, cisplatin and capecitabine combination is effective and well tolerated in Turkish patients with advanced gastric cancer, and could be one of the standard regimens for the first-line treatment in this cohort.en_US
dc.identifier.doi10.4999/uhod.161429
dc.identifier.endpage102en_US
dc.identifier.issn1306-133X
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-84979041823
dc.identifier.scopusqualityQ4
dc.identifier.startpage96en_US
dc.identifier.trdizinid202414
dc.identifier.urihttps://doi.org/10.4999/uhod.161429
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/202414
dc.identifier.urihttps://hdl.handle.net/11468/19836
dc.identifier.volume26en_US
dc.identifier.wosWOS:000388274800005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdvanced Gastric Canceren_US
dc.subjectCisplatinen_US
dc.subjectCapecitabineen_US
dc.subjectEfficacyen_US
dc.subjectToxicityen_US
dc.titleEfficacy and Toxicity of Cisplatin and Capecitabine Combination in the First-Line Treatment of Patients with Advanced Gastric Cancer: A Multicenter Study by the Anatolian Society of Medical Oncologyen_US
dc.titleEfficacy and Toxicity of Cisplatin and Capecitabine Combination in the First-Line Treatment of Patients with Advanced Gastric Cancer: A Multicenter Study by the Anatolian Society of Medical Oncology
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu